Nexus Pharmaceuticals Secures FDA Approval For Methylene Blue Injection
Nexus Pharmaceuticals receives FDA approval for Methylene Blue Injection, a treatment for acquired methemoglobinemia.
Breaking News
Nov 27, 2024
Simantini Singh Deo

Nexus Pharmaceuticals, LLC has received FDA approval for its Methylene Blue Injection, USP. This medication is used to treat acquired methemoglobinemia, a condition affecting oxygen levels in the blood. The injection, available as 50 mg/10 mL (5 mg/mL) (0.5%), will be sold in cartons containing five single-dose 10 mL vials.
Sridhar Desikan, Chief Scientific Officer at Nexus Pharmaceuticals, said in a statement, “We are pleased to strengthen the supply of an AP-rated and TIAA compliant Methylene Blue Injection. The addition of Methylene Blue to our portfolio further emphasizes Nexus’ persistent ambition to provide life-saving medicine to those who need it most.”
Nexus Pharmaceuticals, LLC, a healthcare company in the U.S., focuses on creating specialty and generic drugs that are easier to use and require less effort to prepare. The company ensures its high-quality medicines address urgent medical needs and provide reliable, life-saving treatment options wherever they’re needed.